Session » Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster I

Date: Sunday, November 5, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 768

A Positive Feedback Loop between Estrogen and IL-6 Leads to Fibrosis in Human Skin

9:00AM-11:00AM: Abstract Number: 760

Antisense Long Noncoding RNA HAND2-AS1 and OTUD6B-AS1 Have Important Roles in the Pathogenesis of Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 764

Application of a Novel Computational Approach to Identify New Targets and Pathways for Therapeutic Intervention in Scleroderma

9:00AM-11:00AM: Abstract Number: 776

Circulating Fibrocytes in Systemic Sclerosis Patients and Healthy Subjects: An in Vitro Study

9:00AM-11:00AM: Abstract Number: 767

Elevated MeCP2 Expression in Diffuse Cutaneous Systemic Sclerosis Dermal Fibroblasts Is Associated with Anti-Fibrotic Effects

9:00AM-11:00AM: Abstract Number: 755

Genome-Wide DNA Methylation Pattern in Systemic Sclerosis Microvascular Endothelial Cells: Identification of Epigenetically Affected Key Genes and Pathways

9:00AM-11:00AM: Abstract Number: 758

Identification of Biomarkers Predictive of Pulmonary Arterial Hypertension in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 761

Increased Expression of the TNF Superfamily Member LIGHT/TNFSF14 and Its Receptor (TNFRSF14) in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 766

Increased Plasma Levels of Hsp90 Are Associated with More Severe Organ Involvement in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 770

Integrating Analysis of Skin RNA in Situ Hybridization Using Rnascope and Whole Skin Gene Expression in Systemic Sclerosis Skin to Localize Key Pathogenic Drivers of Skin Fibrosis

9:00AM-11:00AM: Abstract Number: 754

Interferon Siganture in Systemic Sclerosis Lung Microvascular Endothelial Cells

9:00AM-11:00AM: Abstract Number: 762

M10, a Caspase Cleavage Product of the Hepatocyte Growth Factor Receptor, Downregulates Bone Morphogenetic Protein-9-Induced Smad1/5/8 Phosphorylation and Collagen Production in Human Lung Fibroblasts

9:00AM-11:00AM: Abstract Number: 763

Mechanisms of Insulin-like Growth Factor-II-Mediated Fibrosis

9:00AM-11:00AM: Abstract Number: 772

Molecular Mechanism for the Therapeutic Effect of Extracorporeal Shock Wave Therapy on Digital Ulcers of Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 759

Multi Dimensional Analysis of the Immunome in Systemic Sclerosis Reveals Functionally Related Abnormalities in MAIT and B Cell Compartments

9:00AM-11:00AM: Abstract Number: 756

Novel Machine Learning Classifier Accurately Predicts Intrinsic Molecular Subsets for Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 757

Plasmacytoid Dendritic Cells Activated through TLR8 Promote Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 769

Proteomic Analysis of Human Fibroblasts in Systemic Sclerosis Reinforces the Role of Transforming Growth Factor-ß and Points Toward Epidermal Growth Factor Receptor / Phosphatidylinositol 3 Kinase Pathway Inhibition

9:00AM-11:00AM: Abstract Number: 765

Proteomic Analysis of Scleroderma Associated Joint Disease

9:00AM-11:00AM: Abstract Number: 771

Serological Biomarkers of Collagen Formation Is Increased in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 753

The Histone Demethylase Jumonji Domain-Containing Protein 3 (JMJD3) As Central Mediator of Fibroblast Activation

9:00AM-11:00AM: Abstract Number: 773

The Immunophenotyping of Peripheral Blood Associates with Nailfold Microvascular Changes in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 774

The αV Integrin Inhibitor Abituzumab Inhibits Myofibroblast Differentiation

9:00AM-11:00AM: Abstract Number: 775

Transcriptome Sequencing Reveals Genetic Polymorphisms Associated with Ssc Gene Expression Subtypes

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].